Today we are announcing a $311M Series E to bring pharma into the 21st century. Enveda started with a thesis: a molecule that evolution has already refined is a better place to begin than one designed from scratch. This year, two first-in-class molecules discovered by Enveda (ENV-294 and ENV-308) had positive readouts in humans. Many more are behind them. We are grateful to @CatalioCapital for leading this round, to our new investors Durable Capital Partners, @ICONIQCapital, @lightspeedvp, Surveyor Capital (a Citadel company), accounts advised by @TRowePrice, @digitalisvc and Alderline Group, and to @BaillieGifford, @PremjiInvest, @trueventures, @KinnevikAB, @FPVventures, @_DimensionCap, @lifeforcecap and @Lux_Capital for continuing to back us. The best is yet to come… Read more: businesswire.com/news/home/2… #Biotech #AI #LearningfromLife

We are proud to announce our latest milestone at Enveda: FDA IND clearance and first patient dosed for ENV-308, our first-in-class oral therapy for obesity. GLP-1s changed expectations for weight loss. But they also raised challenging questions: Can patients stay on them long term? What happens after weight loss? Who can realistically access injectable medicines on a global scale? ENV-308 is a once-daily oral small molecule designed with exciting potential for durability, tolerability, and real-world use. It’s built for long-term metabolic health, not just short-term weight loss. And it’s designed to fit into everyday life, earlier in care and over years, not months. Obesity is a chronic disease. Solving it at the population scale will require new tools, new thinking, and medicines designed to last. This milestone is a first step. And yes, we are now a multi-asset clinical-stage company! Read more: tinyurl.com/835rd7jc

Raising $150M wasn’t the only headline. Discovery is nothing without delivery ENV-294, our lead drug for #atopicdermatitis, has entered Phase 1b. A completely new way of tackling this disease, and potentially others across #inflammation, is playing out in patients. Experience that shapes the industry Mikael Dolsten joins Enveda. Former CSO of Pfizer, with 36 approvals and 150+ candidates. He knows what it takes to turn science into #medicines that matter. This is just the beginning. Read more in our announcement: businesswire.com/news/home/2…

On the cover… The Great Unknown: Chemistry’s Untapped Frontier in Understanding Life Behind every groundbreaking biological discovery lies a hidden chemical dance—millions of unseen reactions occurring every second. Our research published in @GENBiotechJrnl spotlights #chemistry as biology’s final frontier and how AI is elucidating these invisible reactions. This insight will revolutionize and redefine our understanding of not just life, but what it means to be alive. Honored and excited to see our work featured on the cover of GEN Biotechnology Journal! It’s time for chemistry to take center stage. Read the full article written by our very own Dan Wee, PhD and Tendai Chisowa, PhD: doi.org/10.1089/genbio.2025.… Thank you to @xiaofei_lin and @KevinADavies from @GENbio

More than a clinical milestone – this marks real momentum for our lead asset. Our first-in-class oral therapeutic, ENV-294, cleared a major Phase I milestone with favorable safety results and it's showing potential to transform care for #atopicdermatitis patients. Read more: businesswire.com/news/home/2… Why does this matter? Because 200M+ people worldwide live with atopic dermatitis—yet, there’s a massive unmet need for safe, effective, and convenient options. We are excited to be launching our Phase 1b trial later this year, designed to further evaluate safety, tolerability, pharmacokinetics, target engagement, and early signs of efficacy in atopic dermatitis patients… stay tuned. #DrugDiscovery #AI #ClinicalTrials #Biotech #Inflammation

🚀 We’ve been backed by leading investors behind @SpaceX, @amazon, and other world-changing companies, and now we’re adding one of the biggest names in #pharma to our list. Today, we’re excited to share that Sanofi has joined our Series C syndicate, bringing the total raise to $150M! Our platform leverages #AI to sequence #lifeschemistry and beats  industry averages for #drugdiscovery across time, cost, and outcomes. We’re just getting started. We have several more clinical trials set to start this year… stay tuned! 🔗 Read more: businesswire.com/news/home/2… #biotech #innovation #learningfromlife

#Asthma affects >250M people worldwide and has seen no new meaningful drug approvals in over a decade. Today, Enveda is announcing  that we are expanding our first-in-class lead asset, ENV-294 in asthma, along with a world-class Asthma Advisory Board. Read more here: tinyurl.com/eczpyanc #biotech #AI #innovation

We’re thrilled to introduce something special today… The inaugural issue of 𝗜𝗻-𝗩𝗲𝗱𝗮, a periodic collection of our thoughts and findings at the intersection of technology, science, and humanity. We believe sharing the stories, breakthroughs, and perspectives that shape our world, industry, and lives is essential. In each issue, we’ll give you a window into the advancements, bold ideas, and relentless dedication that drive us forward. In-Veda is more than just an online publication, it’s a reflection of who we are as a company, a community, and as people. Whether you’re an industry leader, partner, investor, or a passionate advocate for science and patient care, we invite you to engage with our vision and be part of this journey. Welcome to In-Veda. Read more: enveda.com/in-veda

We’re thrilled to announce $130M in Series C funding led by @KinnevikAB and FPV, with participation from @BaillieGifford , @premjiinvest , @Lux_Capital , @trueventures , and many more new and existing partners. With this new capital, we plan to advance multiple drug candidates through Phase 1/2 clinical trials. In just 4 short years since our seed round, we’ve gone from a concept to a clinical-stage company with a deep pipeline of 10 development candidates. 🚀 Thanks to the hard work of our team and the power of our platform, we’re delivering drug candidates 4x faster than industry average—a testament to our thesis, technology, and team. This marks a significant step forward in our journey to transform the future of drug discovery. A heartfelt thank you to our investors, partners, and, most importantly, our talented team for making this possible. Here’s to the next chapter of growth, discovery, and development! 💊💡 Learn more here: tinyurl.com/545v3bwu Read our feature in @Bloomberg here: tinyurl.com/yj4e8j8f